Imagen de Portada

Letter on “Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China”

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Ersel Bilgin, Bilger Çavuş, Sabahattin Kaymakoğlu
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
por: Dong Hyun Kim, et al.
Publicado: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
por: Ning Yu, et al.
Publicado: (2025)

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
por: Yanxue Lin, et al.
Publicado: (2025)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
por: Hsiang‐Ting Keng, et al.
Publicado: (2026)

Clinical Trial: Hepatitis B Virus Genotype and a Combination of End‐of‐Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation
por: Arno Furquim d’Almeida, et al.
Publicado: (2025)

Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10‐Year French Nationwide Cohort Study
por: Laurent Lam, et al.
Publicado: (2024)

Editorial: A Step Back to Leap Forward—Strategic Nucleos(t)ide Analogue Discontinuation Towards HBV Functional Cure
por: Xuwen Xu, et al.
Publicado: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
por: Tyng‐Yuan Jang, et al.
Publicado: (2025)

Editorial on ‘Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation: A Pooled Analysis of Two Clinical Trials’
por: Ming Chao Tsai, et al.
Publicado: (2025)

Dynamics of Circulatory HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation Using iTACT Assays to Predict Clinical Flares and HBsAg Loss
por: Ying‐Nan Tsai, et al.
Publicado: (2026)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
por: YaoYao Dai, et al.
Publicado: (2025)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
por: Paul Y. Kwo, et al.
Publicado: (2026)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
por: Muhammad Osama, et al.
Publicado: (2024)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
por: Maria Buti
Publicado: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
por: Yi‐Ping Hung, et al.
Publicado: (2024)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
por: Nina Dominik, et al.
Publicado: (2024)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
por: Bi‐Yu Gao, et al.
Publicado: (2025)

Letter: Assessing the Durability of Treatment Effects: Long‐Term Outcomes of ESWL and ERCP for Pancreatic Duct Stones in Chronic Pancreatitis
por: Wei‐Zhen Tang, et al.
Publicado: (2024)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
por: Qiong Yi, et al.
Publicado: (2024)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks
por: Chun‐Chieh Chen, et al.
Publicado: (2025)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
por: Pei‐Chien Tsai, et al.
Publicado: (2025)

Letter on ‘Post‐TIPS Overt Hepatic Encephalopathy Increases Long‐Term but Not Short‐Term Mortality in Cirrhotic Patients With Variceal Bleeding: A Large‐Scale, Multicentre Real‐World’
por: Silvia Nardelli, et al.
Publicado: (2025)

Systematic Review: Incidence of Liver‐Related Events in People Living With Hepatitis Delta Virus
por: Laura E. Telep, et al.
Publicado: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
por: Rui Huang, et al.
Publicado: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
por: Eunice Yewon Lee, et al.
Publicado: (2024)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
por: Dong Hyun Kim, et al.
Publicado: (2025)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal
por: Edo J. Dongelmans, et al.
Publicado: (2026)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
por: Benedikt Silvester Hofer, et al.
Publicado: (2026)

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?
por: Miriam T. Levy
Publicado: (2026)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
por: Jian Wang, et al.
Publicado: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
por: Ewan Forrest, et al.
Publicado: (2025)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal. Authors' Reply
por: Yasuhito Tanaka, et al.
Publicado: (2026)

Virological and Immunological Characteristics of HBeAg ‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels
por: Yuxin Chen, et al.
Publicado: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
por: Eiichi Ogawa
Publicado: (2024)

Letter: ‘Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study’
por: Matthias Kelm, et al.
Publicado: (2025)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
por: Muhammad Ibrahim Khalil, et al.
Publicado: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
por: Francisco Idalsoaga, et al.
Publicado: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations
por: Zhen Deng, et al.
Publicado: (2025)

Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients
por: Ming Liu, et al.
Publicado: (2025)

Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long‐Term Outcomes: The ERIC Study: Authors' Reply
por: Nathan Grellier, et al.
Publicado: (2025)